{"protocolSection":{"identificationModule":{"nctId":"NCT01130103","orgStudyIdInfo":{"id":"R01MH068173","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R01MH068173"},"secondaryIdInfos":[{"id":"R01MH068173","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R01MH068173"}],"organization":{"fullName":"Research Foundation for Mental Hygiene, Inc.","class":"OTHER"},"briefTitle":"Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack","officialTitle":"Combination Treatment for PTSD After the WTC Attack"},"statusModule":{"statusVerifiedDate":"2012-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-03"},"primaryCompletionDateStruct":{"date":"2010-02","type":"ACTUAL"},"completionDateStruct":{"date":"2010-02","type":"ACTUAL"},"studyFirstSubmitDate":"2010-05-24","studyFirstSubmitQcDate":"2010-05-24","studyFirstPostDateStruct":{"date":"2010-05-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-07-09","resultsFirstSubmitQcDate":"2012-07-09","resultsFirstPostDateStruct":{"date":"2012-08-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-11-30","lastUpdatePostDateStruct":{"date":"2012-12-04","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Franklin Schneier","investigatorTitle":"Research Psychiatrist","investigatorAffiliation":"Research Foundation for Mental Hygiene, Inc."},"leadSponsor":{"name":"Research Foundation for Mental Hygiene, Inc.","class":"OTHER"},"collaborators":[{"name":"National Institute of Mental Health (NIMH)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This randomized controlled trial evaluates efficacy of combined prolonged exposure (PE) and the selective serotonin reuptake inhibitor (SSRI) paroxetine in the treatment of survivors of the World Trade Center (WTC) attacks.","detailedDescription":"Selective serotonin reuptake inhibitor (SSRI) medication is often recommended in combination with cognitive behavioral therapies for PTSD, but combined initial treatment of PTSD has not been studied under controlled conditions. Also, there are few studies of either treatment in survivors of terrorism. This randomized controlled trial evaluates efficacy of combined prolonged exposure (PE) and the SSRI paroxetine in the treatment of survivors of the World Trade Center (WTC) attacks."},"conditionsModule":{"conditions":["Posttraumatic Stress Disorder"],"keywords":["PTSD","anxiety disorders","trauma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":37,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Paroxetine","type":"EXPERIMENTAL","description":"Paroxetine and Prolonged Exposure Therapy","interventionNames":["Drug: Paroxetine","Behavioral: Prolonged Exposure Therapy"]},{"label":"Placebo pill","type":"PLACEBO_COMPARATOR","description":"Placebo pill plus Prolonged Exposure Therapy","interventionNames":["Behavioral: Prolonged Exposure Therapy"]}],"interventions":[{"type":"DRUG","name":"Paroxetine","description":"Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks","armGroupLabels":["Paroxetine"],"otherNames":["Paxil controlled release (CR)"]},{"type":"BEHAVIORAL","name":"Prolonged Exposure Therapy","description":"Weekly for 10 weeks","armGroupLabels":["Paroxetine","Placebo pill"],"otherNames":["Cognitive Behavioral Therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Clinician Administered PTSD Scale (CAPS)","description":"PTSD severity, minimum = 0 = no symptoms of PTSD maximum = 136 = extremely severe symptoms of PTSD","timeFrame":"Weeks 0,5,10"},{"measure":"Number of Participants Who Met Remission Criterion","description":"remission defined as: CAPS less than or equal to 20 and Clinical Global Impression (CGI)-change score=1","timeFrame":"Weeks 5,10"}],"secondaryOutcomes":[{"measure":"Treatment Response at Weeks 5 and 10","description":"responder status: CGI-change score of 1 or 2\n\n1=very much improved, 2= much improved","timeFrame":"weeks 5,10"},{"measure":"Hamilton Depression Scale 0 = no Depression Symptoms 40 = Extreme Depression Symptoms","description":"total score at weeks 0, 5, 10","timeFrame":"weeks 0,5,10"},{"measure":"Quality of Life Enjoyment and Satisfaction Scale Total Score at Week 0,5,10","description":"Measures life enjoyment and satisfaction across 16 domains 16 = very poor quality of life to 80 =very good quality of life","timeFrame":"weeks 0,5,10"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Posttraumatic Stress Disorder, chronic, related to World Trade Center Attacks\n* Age 18-70\n* CAPS score greater than 45\n* Willingness to consent\n* For women, negative pregnancy test and using adequate birth control\n\nExclusion Criteria:\n\n* Prominent suicidal ideation\n* Current psychotic disorder\n* Unstable medical illness\n* Women who are pregnant or nursing mothers\n* Alcohol or substance use disorder in the past 3 months\n* History of seizure disorder\n* conditions that contraindicate use of paroxetine\n* inability to tolerate a drug free period prior to beginning the study of 4 weeks for MAOIs or fluoxetine and 2 weeks for other psychotropic drugs, except zolpidem for insomnia.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Franklin Schneier, MD","affiliation":"New York State Psychiatric Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"New York State Psychiatric Institute","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}}]},"referencesModule":{"references":[{"pmid":"21908494","type":"DERIVED","citation":"Schneier FR, Neria Y, Pavlicova M, Hembree E, Suh EJ, Amsel L, Marshall RD. Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry. 2012 Jan;169(1):80-8. doi: 10.1176/appi.ajp.2011.11020321. Epub 2011 Sep 9."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Recruitment dates: December, 2004 to February, 2009. Location: Anxiety Disorders research clinic.","groups":[{"id":"FG000","title":"Paroxetine","description":"Paroxetine and Prolonged Exposure Therapy"},{"id":"FG001","title":"Placebo Pill","description":"Placebo pill plus Prolonged Exposure Therapy"}],"periods":[{"title":"Randomized Treatment","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"18"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]}]},{"title":"Maintenance Treatment","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Paroxetine","description":"Paroxetine and Prolonged Exposure Therapy"},{"id":"BG001","title":"Placebo Pill","description":"Placebo pill plus Prolonged Exposure Therapy"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"37"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"37"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"20"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"17"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"37"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Clinician Administered PTSD Scale (CAPS)","description":"PTSD severity, minimum = 0 = no symptoms of PTSD maximum = 136 = extremely severe symptoms of PTSD","populationDescription":"all participants who were randomized","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Weeks 0,5,10","groups":[{"id":"OG000","title":"Paroxetine","description":"Paroxetine and Prolonged Exposure Therapy"},{"id":"OG001","title":"Placebo Pill","description":"Placebo pill plus Prolonged Exposure Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"18"}]}],"classes":[{"title":"week 0","categories":[{"measurements":[{"groupId":"OG000","value":"72.6","spread":"12.9"},{"groupId":"OG001","value":"65.4","spread":"12.8"}]}]},{"title":"week 5","categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":"28.4"},{"groupId":"OG001","value":"49.0","spread":"23.9"}]}]},{"title":"week 10","categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"19.9"},{"groupId":"OG001","value":"35.6","spread":"31.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"caps total score at weeks 5 and 10","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".01","statisticalMethod":"Mixed Models Analysis","paramType":"incident rate ratio","paramValue":"0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":".30","ciUpperLimit":".85"},{"groupIds":["OG000","OG001"],"groupDescription":"rate of change in CAPS total from week 5 to week 10","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"Mixed Models Analysis","paramType":"incident rate ratio","paramValue":".56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":".43","ciUpperLimit":".74"}]},{"type":"SECONDARY","title":"Treatment Response at Weeks 5 and 10","description":"responder status: CGI-change score of 1 or 2\n\n1=very much improved, 2= much improved","populationDescription":"all subjects randomized with dropouts carried forward as nonresponders","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"weeks 5,10","groups":[{"id":"OG000","title":"Paroxetine","description":"Paroxetine and Prolonged Exposure Therapy"},{"id":"OG001","title":"Placebo Pill","description":"Placebo pill plus Prolonged Exposure Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"18"}]}],"classes":[{"title":"week 5","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}]},{"title":"week 10","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Hamilton Depression Scale 0 = no Depression Symptoms 40 = Extreme Depression Symptoms","description":"total score at weeks 0, 5, 10","populationDescription":"observed data at each time point","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"weeks 0,5,10","groups":[{"id":"OG000","title":"Paroxetine","description":"Paroxetine and Prolonged Exposure Therapy"},{"id":"OG001","title":"Placebo Pill","description":"Placebo pill plus Prolonged Exposure Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"18"}]}],"classes":[{"title":"week 0","categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":"4.9"},{"groupId":"OG001","value":"16.6","spread":"4.9"}]}]},{"title":"week 5","categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"5.9"},{"groupId":"OG001","value":"11.8","spread":"5.6"}]}]},{"title":"week 10","categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"3.7"},{"groupId":"OG001","value":"11.4","spread":"6.7"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Enjoyment and Satisfaction Scale Total Score at Week 0,5,10","description":"Measures life enjoyment and satisfaction across 16 domains 16 = very poor quality of life to 80 =very good quality of life","populationDescription":"observed data at weeks 0, 5, and 10","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"weeks 0,5,10","groups":[{"id":"OG000","title":"Paroxetine","description":"Paroxetine and Prolonged Exposure Therapy"},{"id":"OG001","title":"Placebo Pill","description":"Placebo pill plus Prolonged Exposure Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}]}],"classes":[{"title":"week 0","categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":"11.0"},{"groupId":"OG001","value":"45.4","spread":"18.5"}]}]},{"title":"week 5","categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":"13.4"},{"groupId":"OG001","value":"59.4","spread":"17.6"}]}]},{"title":"week 10","categories":[{"measurements":[{"groupId":"OG000","value":"67.9","spread":"12.7"},{"groupId":"OG001","value":"54.8","spread":"22.3"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Met Remission Criterion","description":"remission defined as: CAPS less than or equal to 20 and Clinical Global Impression (CGI)-change score=1","populationDescription":"all participants who were randomized, with people who dropped out counted as non-remitters","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Weeks 5,10","groups":[{"id":"OG000","title":"Paroxetine","description":"Paroxetine and Prolonged Exposure Therapy"},{"id":"OG001","title":"Placebo Pill","description":"Placebo pill plus Prolonged Exposure Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"18"}]}],"classes":[{"title":"week 5","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"week 10","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"treatment group effect: remission rate at weeks 5 and 10","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".03","statisticalMethod":"Mixed Models Analysis","paramType":"Odds Ratio (OR)","paramValue":"12.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.23","ciUpperLimit":"129"},{"groupIds":["OG000","OG001"],"groupDescription":"rate of change over time in remission rate from week 5 to 10","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","statisticalMethod":"Mixed Models Analysis","paramType":"Odds Ratio (OR)","paramValue":"20.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.44","ciUpperLimit":"176"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Paroxetine","description":"Paroxetine and Prolonged Exposure Therapy","seriousNumAffected":0,"seriousNumAtRisk":19,"otherNumAffected":6,"otherNumAtRisk":19},{"id":"EG001","title":"Placebo Pill","description":"Placebo pill plus Prolonged Exposure Therapy","seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":5,"otherNumAtRisk":18}],"otherEvents":[{"term":"headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"palpitations","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":19},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":18}]},{"term":"nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":19},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"sweating","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"photophobia","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"tachycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":19},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":19},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"lightheadedness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"dry mouth","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"blurry vision","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"parasthesias","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"decrease libido","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":19},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"anorgasmia","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"impaired coordination","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"nervousness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"insomnia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"weight gain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"weight loss","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"skin problems","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"difficulty urinating","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":18}]},{"term":"rigidity","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"somnolence","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":18}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"pointOfContact":{"title":"Franklin Schneier MD","organization":"Research Foundation for Mental Hygiene","email":"frs1@columbia.edu","phone":"212-543-5368"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D013313","term":"Stress Disorders, Post-Traumatic"},{"id":"D001008","term":"Anxiety Disorders"},{"id":"D014947","term":"Wounds and Injuries"}],"ancestors":[{"id":"D040921","term":"Stress Disorders, Traumatic"},{"id":"D000068099","term":"Trauma and Stressor Related Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D017374","term":"Paroxetine"},{"id":"D015928","term":"Cognitive Behavioral Therapy"}],"ancestors":[{"id":"D010880","term":"Piperidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D001521","term":"Behavior Therapy"},{"id":"D011613","term":"Psychotherapy"},{"id":"D004191","term":"Behavioral Disciplines and Activities"}]}},"hasResults":true}